Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 11/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | MYLK | Q15746 | 3/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18969217 | 0.90 | WEE1 (0.37) | WEE1CHEK1SRCMYLKCDK1 | |
| SCHEMBL13637211 | 0.87 | WEE1 (0.46) | WEE1CHEK1SRCMYLKCDK1 | |
| SCHEMBL12608681 | 0.81 | WEE1 (0.43) | WEE1CHEK1SRCMYLKCDK1 | |
| SCHEMBL2360961 | 0.81 | CNR2 (0.42) | WEE1CHEK1SRCCNR2CSF1R | |
| SCHEMBL2361050 | 0.78 | TP53 (0.47) | WEE1CHEK1SRCMYLKCDK1 | |
| SCHEMBL12608686 | 0.76 | WEE1 (0.44) | WEE1CHEK1SRCMYLKCDK1 | |
| SCHEMBL13419058 | 0.76 | WEE1 (0.42) | WEE1CHEK1SRCMYLKCDK1 | |
| SCHEMBL12608693 | 0.75 | CNR2 (0.39) | WEE1CHEK1SRCCNR2CSF1R | |
| SCHEMBL17297962 | 0.75 | CNR2 (0.41) | WEE1CHEK1SRCCNR2CSF1R | |
| SCHEMBL18975952 | 0.74 | WEE1 (0.39) | WEE1CHEK1SRCMYLKCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | WEE1 1071/4885CHEK1 852/4885SRC 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.